Dublin 7

• Pan-tumor Study of I-DXd in Subjects with Recurrent or Metastatic Solid Tumors Recruiting
  2023-509632-26-00 9 2025-02-11 Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head an
• A study to characterise the safety, tolerability and efficacy of LY3962673 in subjects with advanced solid tumors. Recruiting
  2024-516440-25-00 1 2025-02-06 KRAS G12D-mutant solid tumors.
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 Triple Negative Breast Cancer
• A proof-of-concept study to learn whether linvoseltamab can eliminate abnormal plasma cells that may lead to multiple myeloma in adult patie … Recruiting
  2023-505242-25-00 4 2024-11-05 High-Risk Monoclonal Gammopathy of Undetermined Significance; Non-Hig
• Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag … Recruiting
  2023-507482-26-00 5 2024-10-04 Castrate-resistant prostate cancer with oligometastases on functional
• A follow-up study to test long-term treatment with BI 1015550 in people with pulmonary fibrosis who took part in a previous study with BI 10 … Recruiting
  2023-507353-15-00 5 2024-09-10 idiopathic pulmonary fibrosis (IPF)
• Trastuzumab Deruxtecan (T-DXd) for Subjects with Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC0 Breast Cancer … Recruiting
  2023-505616-38-00 4 2024-09-04 Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (
• A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alt … Recruiting
  2023-507684-19-00 5 2024-07-24 FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer
• Phase 3 study to assess the efficacy and safety of Givinostat versus hydroxyurea in Polycythemia Vera patients Recruiting
  2022-502276-23-00 5 2024-04-25 JAK2V617F-positive high-risk Polycythemia Vera
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi … Recruiting
  2022-501453-36-00 5 2024-02-23 Breast cancer
• A study of STX-478 alone and in combination with other anticancer drugs in participants with advanced solid tumors. Recruiting
  2023-504807-94-00 7 2023-12-26 Breast Cancer; Advanced solid tumors including but not limited to gyne
• Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3) Recruiting
  2022-500587-35-01 5 2023-07-06 Stroke
• A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting
  2024-514180-25-00 5 2022-11-21 unresectable or metastatic HER2+ colorectal cancer
• Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable Non-small Cell Lung Cancer Recruiting
  2023-508852-21-00 4 2022-06-10 Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer
• A randomised, controlled, parallel group, open-label trial evaluating the impact of treatment with the GLP-1 analogue semaglutide on weight … Recruiting
  2024-513168-24-00 4 2022-06-01 HIV & Obesity
• EPO-TRAUMA Recruiting
  2023-506081-31-00 5 2022-03-29 Traumatic Injury
• Extension Study for Participants in Studies That Include Pembrolizumab Recruiting
  2022-501254-10-00 5 2018-08-24 Advanced tumors
• A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients with Lung Fibr … Ended recruitment
  2024-511754-41-00 4 2025-05-29 idiopathic pulmonary fibrosis
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended recruitment
  2024-512925-95-00 5 2025-05-16 Advanced/Metastatic Breast Cancer
• Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended recruitment
  2024-510730-40-00 5 2024-12-12 Hidradenitis Suppurativa
• A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Rec … Ended recruitment
  2023-505617-24-00 4 2024-11-05 Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression
• An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arte … Ended recruitment
  2023-506334-75-00 5 2024-07-12 Pulmonary Arterial Hypertension
• Add-Aspirin: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and surv … Ended recruitment
  2024-511306-23-00 5 2024-07-01 Breast cancer, colon cancer, rectal cancer, stomach cancer, oesophagea

Showing 49–72 of 126 trials